*Autoimmune pancreatitis (AIP) is a steroid-responsive fibroinflammatory disease of the pancreas that can closely mimic pancreatic malignancy.* --- ### Essential Takeaway The major clinical challenge in AIP is **distinguishing it from pancreatic cancer**. Diagnosis integrates **pancreatic imaging, serum IgG4, other-organ involvement, histology, and occasionally response to corticosteroids**. - **Type 1 AIP** is a manifestation of systemic IgG4-related disease and commonly presents with painless jaundice. - **Type 2 AIP** is pancreas-specific, often associated with IBD, and more commonly presents with acute pancreatitis. - **Serum IgG4 alone is not diagnostic.** - **Exclude malignancy before considering a diagnostic steroid trial.** --- ## Presentation ### Type 1 vs. Type 2 AIP | Feature | Type 1 AIP | Type 2 AIP | | ------------------ | ------------------------------------------------ | ------------------------------------ | | Disease | IgG4-related disease | Idiopathic duct-centric pancreatitis | | Typical patient | Older, male predominance | Younger | | Presentation | Painless jaundice, pancreatic mass | Acute pancreatitis, abdominal pain | | Serum IgG4 | Frequently elevated | Usually normal | | Histology | Lymphoplasmacytic sclerosing pancreatitis (LPSP) | Granulocytic epithelial lesions | | Associated disease | Systemic IgG4-RD | IBD, particularly UC | | Relapse | Relatively common | Uncommon | ### Clinical Features **Type 1 AIP** - Painless obstructive jaundice - Pancreatic enlargement or focal pancreatic mass - Weight loss - New or worsening diabetes mellitus - Mild abdominal discomfort - Occasionally acute pancreatitis **Type 2 AIP** - Acute pancreatitis - Abdominal pain - Concurrent inflammatory bowel disease ### Other-Organ Involvement Type 1 AIP may occur alongside other manifestations of IgG4-related disease: - **IgG4-related sclerosing cholangitis** - Salivary or lacrimal gland enlargement - Renal lesions - Retroperitoneal fibrosis - Lymphadenopathy - Pulmonary involvement --- ## Workup ### 1. Cross-Sectional Imaging Obtain **pancreatic-protocol CT or MRI/MRCP**. **Findings favoring AIP:** - Diffuse, "sausage-shaped" pancreatic enlargement - Loss of normal pancreatic lobulation - Capsule-like peripheral rim - Homogeneous delayed enhancement - Long-segment or multifocal pancreatic duct strictures - Minimal upstream pancreatic duct dilation - Duct-penetrating sign through a focal lesion - Associated biliary or extrapancreatic IgG4-RD findings **Features concerning for PDAC:** - Discrete hypovascular mass - Abrupt pancreatic duct cutoff - Significant upstream duct dilation - Distal pancreatic atrophy - Vascular invasion - Metastatic disease > **Clinical Pearl:** Focal AIP can be radiographically indistinguishable from PDAC. Imaging findings alone should not be used to exclude malignancy. ### 2. Laboratory Evaluation Recommended testing: - **Serum IgG4** - Liver chemistries and bilirubin - CBC / CMP - Glucose or HbA1c - CA 19-9 when malignancy is suspected **Serum IgG4 interpretation:** | Finding | Interpretation | |---|---| | Normal IgG4 | Does not exclude AIP | | > Upper limit of normal | Supportive but nonspecific | | > 2× ULN | Stronger evidence for type 1 AIP (ICDC level 1 serology) | Mild IgG4 elevations may also occur in pancreatic cancer and other inflammatory diseases. ### 3. EUS ± Core Biopsy Consider EUS-guided tissue acquisition when: - Focal pancreatic mass is present - Imaging is atypical - Serology and other-organ findings are inconclusive - Malignancy cannot confidently be excluded **EUS-guided fine-needle biopsy (FNB)** is preferred over cytology alone when histologic diagnosis of AIP is required. **Type 1 — LPSP:** - Dense lymphoplasmacytic inflammation - Storiform fibrosis - Obliterative phlebitis - Increased IgG4-positive plasma cells **Type 2 — IDCP:** - Granulocytic epithelial lesions involving pancreatic ducts - Usually without elevated IgG4 ### 4. Diagnostic Criteria The **International Consensus Diagnostic Criteria (ICDC)** incorporate five domains: 1. Pancreatic parenchymal and ductal imaging 2. Serum IgG4 3. Other-organ involvement 4. Pancreatic histology 5. Response to corticosteroids These are combined to establish definite or probable type 1 or type 2 AIP. ### 5. Diagnostic Steroid Trial A rapid clinical and radiographic response to corticosteroids supports the diagnosis of AIP. However, **empiric corticosteroids should not be initiated for a pancreatic mass until an appropriate malignancy evaluation has been completed**. If a diagnostic trial is undertaken: - Establish objective baseline imaging and laboratory findings - Initiate corticosteroids under specialist supervision - Reassess clinical, biochemical, and imaging response after approximately **2 weeks** - Reconsider malignancy if the expected objective response is absent --- ## Treatment ### Indications for Treatment Treatment is generally recommended for: - Obstructive jaundice - Symptomatic pancreatic inflammation - Abdominal pain - IgG4-related cholangitis - Clinically significant other-organ involvement Selected asymptomatic patients may warrant treatment if persistent inflammation threatens irreversible organ dysfunction. ### First-Line: Corticosteroids **Prednisone 0.6–0.8 mg/kg/day**, commonly **30–40 mg/day**. Typical approach: 1. Induction for approximately **2–4 weeks** 2. Confirm clinical, biochemical, and radiographic response 3. Gradual taper over approximately **2–3 months** Most patients experience rapid improvement with corticosteroid therapy. ### Biliary Obstruction ERCP with biliary drainage may be required for: - Cholangitis - Severe or persistent biliary obstruction - Diagnostic evaluation requiring ERCP-based tissue acquisition Biliary strictures related to IgG4-RD frequently improve with corticosteroid therapy. ### Relapsed or Refractory Disease Relapse occurs primarily in **type 1 AIP**. Management options include: - Repeat corticosteroid induction - Low-dose maintenance corticosteroids - Steroid-sparing immunomodulators (e.g., azathioprine, mycophenolate) - **Rituximab** for recurrent, steroid-dependent, or refractory IgG4-related disease Maintenance therapy is individualized, particularly for patients with recurrent disease, biliary involvement, or multiorgan IgG4-RD. ### Role of Surgery **AIP itself is not an indication for pancreatic resection.** Surgery is generally reserved for patients in whom malignancy cannot be excluded despite an appropriate diagnostic evaluation. --- ## Surveillance / Long-Term Risks ### Relapse Type 1 AIP carries a substantial risk of relapse, whereas recurrence of type 2 AIP is uncommon. Risk factors associated with relapse include: - IgG4-related sclerosing cholangitis - Multiorgan involvement - Persistently elevated serum IgG4 - Previous relapse Long-term follow-up should assess for recurrent pancreatic and extrapancreatic disease. ### Suggested Follow-Up There is no universally standardized surveillance schedule. A practical approach for type 1 AIP includes: - **Clinical assessment:** Every 3–6 months initially, then individualized - **Liver chemistries:** Particularly with previous biliary involvement - **Serum IgG4:** When elevated at baseline; trends are supportive but not diagnostic of relapse - **CT or MRI/MRCP:** To document treatment response and evaluate suspected relapse - **Glucose / HbA1c:** Periodic assessment - **Exocrine function:** Evaluate for steatorrhea, weight loss, or malabsorption Follow-up intensity should reflect relapse risk, prior organ involvement, and maintenance therapy. ### Pancreatic Dysfunction Potential long-term complications include: - **Diabetes mellitus** - **Pancreatic exocrine insufficiency** - Pancreatic atrophy - Chronic pancreatitis and calcifications Evaluate for endocrine and exocrine insufficiency during follow-up. ### Malignancy Risk The relationship between AIP and pancreatic malignancy remains incompletely defined. - Some observational studies suggest increased malignancy incidence, particularly near the time of AIP diagnosis. - A causal association between AIP and PDAC has not been established. - There is **no established pancreatic cancer surveillance protocol solely for AIP**. A new pancreatic mass, progressive ductal obstruction, unexplained weight loss, or atypical response to corticosteroids warrants renewed evaluation for malignancy rather than presumed AIP relapse. --- ### References >[!quote]- References >1. Shimosegawa T, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. *Pancreas.* 2011;40:352–358. [PubMed](https://pubmed.ncbi.nlm.nih.gov/21412117/) >2. Okazaki K, et al. International consensus for the treatment of autoimmune pancreatitis. *Pancreatology.* 2017;17:1–6. >3. Löhr JM, et al. European Guideline on IgG4-related digestive disease: UEG and SGF evidence-based recommendations. *United European Gastroenterol J.* 2020. >4. Lanzillotta M, et al. Update on Autoimmune Pancreatitis and IgG4-Related Disease. *United European Gastroenterol J.* 2025. Last updated: 10/27/2026